- Home
- BODI vs IXHL Comparison
BODI vs IXHL Comparison
Compare BODI & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BODI
- IXHL
- Stock Information
- Founded
- BODI 1998
- IXHL 2001
- Country
- BODI United States
- IXHL Australia
- Employees
- BODI N/A
- IXHL N/A
- Industry
- BODI Industrial Machinery/Components
- IXHL
- Sector
- BODI Industrials
- IXHL
- Exchange
- BODI Nasdaq
- IXHL Nasdaq
- Market Cap
- BODI 46.9M
- IXHL 49.1M
- IPO Year
- BODI N/A
- IXHL N/A
- Fundamental
- Price
- BODI $4.24
- IXHL $0.36
- Analyst Decision
- BODI Buy
- IXHL
- Analyst Count
- BODI 2
- IXHL 0
- Target Price
- BODI $10.00
- IXHL N/A
- AVG Volume (30 Days)
- BODI 13.8K
- IXHL 25.6M
- Earning Date
- BODI 11-10-2025
- IXHL 11-14-2025
- Dividend Yield
- BODI N/A
- IXHL N/A
- EPS Growth
- BODI N/A
- IXHL N/A
- EPS
- BODI N/A
- IXHL N/A
- Revenue
- BODI $324,871,000.00
- IXHL $86,000.00
- Revenue This Year
- BODI N/A
- IXHL $1,188.37
- Revenue Next Year
- BODI N/A
- IXHL N/A
- P/E Ratio
- BODI N/A
- IXHL N/A
- Revenue Growth
- BODI N/A
- IXHL 616.67
- 52 Week Low
- BODI $3.38
- IXHL $0.08
- 52 Week High
- BODI $8.71
- IXHL $3.12
- Technical
- Relative Strength Index (RSI)
- BODI 29.27
- IXHL 44.76
- Support Level
- BODI $4.61
- IXHL $0.34
- Resistance Level
- BODI $5.20
- IXHL $0.41
- Average True Range (ATR)
- BODI 0.39
- IXHL 0.03
- MACD
- BODI -0.10
- IXHL 0.01
- Stochastic Oscillator
- BODI 10.52
- IXHL 33.08
About BODI The Beachbody Company Inc. Class A Common Stock
The Beachbody Co Inc is a health and wellness platform providing fitness, nutrition and stress-reducing programs to its customers. The product offerings of the company include Digital Subscriptions, Nutritional Products, and Connected Fitness Products. It earns the majority of its revenue from the United States. The company operates and manages its business in one operating segment. Majority of revenue is through Digital.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.